ECONOCHLOR

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ECONOCHLOR (ECONOCHLOR).

How it works

Econazole nitrate inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis, disrupting fungal cell membrane integrity and function.

What the body does with it

Metabolism	Minimal systemic absorption following topical application; absorbed drug is extensively metabolized in the liver via oxidative pathways and conjugation.
Excretion	Renal: 80-90% as unchanged drug; fecal: <1%; biliary: minimal.
Half-life	Terminal half-life: 8-10 hours in adults with normal renal function; prolonged to 15-20 hours in renal impairment (CrCl <30 mL/min).
Protein binding	85-90% bound, primarily to albumin.
Volume of Distribution	0.8-1.0 L/kg; indicates distribution into total body water with some tissue binding.
Bioavailability	Oral: 70-80%; Topical: poorly absorbed (1-5% through intact skin); Ophthalmic: negligible systemic absorption (less than 1%).
Onset of Action	Oral: 2-4 hours; Topical: 2-4 weeks (antipruritic effect); Ophthalmic: 3-5 days (anti-inflammatory effect).
Duration of Action	Oral: 12-24 hours; Topical: 2-4 weeks of therapy; Ophthalmic: 3-4 weeks.

Classification & Brands

Dosing & administration

0.12 mg/kg IV bolus over 30 seconds, followed by continuous IV infusion at 0.12-0.6 mg/kg/h.

Dosage form	OINTMENT
Renal impairment	No dose adjustment required for renal impairment.
Liver impairment	Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution, monitor for toxicity; no specific dose reduction established. Child-Pugh Class C: Contraindicated.
Pediatric use	Neonates (<1 month): 0.12 mg/kg IV bolus, then 0.6 mg/kg/h infusion. Infants and children (1 month to 12 years): 0.12 mg/kg IV bolus, then 0.15-0.6 mg/kg/h infusion.
Geriatric use	No specific dose adjustment required; use caution due to increased sensitivity to bradycardia and hypotension.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ECONOCHLOR (ECONOCHLOR).

Breastfeeding

Enters breast milk; M/P ratio 0.6-0.8 (limited data). Risk of infant renal stones, diarrhea, rash. Discontinue breastfeeding or avoid drug. Use only if essential for maternal therapy.

Teratogenic Risk

FDA Pregnancy Category C. In first trimester, fetal risk not definitively established; animal studies show dose-dependent teratogenicity (cleft palate, skeletal abnormalities) at maternally toxic doses. Second trimester: risk of fetal nephrolithiasis, transient renal impairment. Third trimester: neonatal nephrolithiasis, hematuria, oliguria reported with prolonged high dose. Avoid in pregnancy unless benefit outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Common Effects	Eye irritation Burning eyes Eye discomfort Eye itching Eye pain
Serious Effects

Absolute Contraindications

Hypersensitivity to econazole or any component of the formulation.

Clinical Precautions

Precautions	For external use only; avoid contact with eyes, mouth, and mucous membranes; discontinue if irritation or sensitization occurs; use in pregnancy only if clearly needed (Category C).
Food/Dietary	Avoid alcohol; may cause disulfiram-like reaction. No significant food interactions reported.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

ECONOCHLOR

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ECONOCHLOR (ECONOCHLOR).

How it works

Econazole nitrate inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis, disrupting fungal cell membrane integrity and function.

What the body does with it

Metabolism	Minimal systemic absorption following topical application; absorbed drug is extensively metabolized in the liver via oxidative pathways and conjugation.
Excretion	Renal: 80-90% as unchanged drug; fecal: <1%; biliary: minimal.
Half-life	Terminal half-life: 8-10 hours in adults with normal renal function; prolonged to 15-20 hours in renal impairment (CrCl <30 mL/min).
Protein binding	85-90% bound, primarily to albumin.
Volume of Distribution	0.8-1.0 L/kg; indicates distribution into total body water with some tissue binding.
Bioavailability	Oral: 70-80%; Topical: poorly absorbed (1-5% through intact skin); Ophthalmic: negligible systemic absorption (less than 1%).
Onset of Action	Oral: 2-4 hours; Topical: 2-4 weeks (antipruritic effect); Ophthalmic: 3-5 days (anti-inflammatory effect).
Duration of Action	Oral: 12-24 hours; Topical: 2-4 weeks of therapy; Ophthalmic: 3-4 weeks.

Classification & Brands

Dosing & administration

0.12 mg/kg IV bolus over 30 seconds, followed by continuous IV infusion at 0.12-0.6 mg/kg/h.

Dosage form	OINTMENT
Renal impairment	No dose adjustment required for renal impairment.
Liver impairment	Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution, monitor for toxicity; no specific dose reduction established. Child-Pugh Class C: Contraindicated.
Pediatric use	Neonates (<1 month): 0.12 mg/kg IV bolus, then 0.6 mg/kg/h infusion. Infants and children (1 month to 12 years): 0.12 mg/kg IV bolus, then 0.15-0.6 mg/kg/h infusion.
Geriatric use	No specific dose adjustment required; use caution due to increased sensitivity to bradycardia and hypotension.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ECONOCHLOR (ECONOCHLOR).

Breastfeeding

Enters breast milk; M/P ratio 0.6-0.8 (limited data). Risk of infant renal stones, diarrhea, rash. Discontinue breastfeeding or avoid drug. Use only if essential for maternal therapy.

Teratogenic Risk

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Common Effects	Eye irritation Burning eyes Eye discomfort Eye itching Eye pain
Serious Effects

Absolute Contraindications

Hypersensitivity to econazole or any component of the formulation.

Clinical Precautions

Precautions	For external use only; avoid contact with eyes, mouth, and mucous membranes; discontinue if irritation or sensitization occurs; use in pregnancy only if clearly needed (Category C).
Food/Dietary	Avoid alcohol; may cause disulfiram-like reaction. No significant food interactions reported.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

Clinical Pearls	ECONOCHLOR (chloramphenicol) is a bacteriostatic antibiotic that inhibits protein synthesis. Monitor for dose-dependent bone marrow suppression, especially with prolonged use. Avoid in neonates due to gray baby syndrome. Use with caution in hepatic impairment; reduce dose. Therapeutic drug monitoring recommended to maintain trough 5-10 mcg/mL.
Patient Advice	Complete full course even if you feel better. · Report unusual bleeding, bruising, or sore throat immediately. · Avoid alcohol during treatment. · Do not use leftover antibiotics. · Notify doctor if pregnant or breastfeeding.